NK Cell Levels Correlate with Disease Activity in Patients with Multiple Sclerosis on Ocrelizumab/Rituximab Therapy

被引:1
|
作者
Dal Bello, Simone [1 ]
Lorenzut, Simone [2 ]
Saccomano, Emma [1 ]
Tereshko, Yan [1 ]
Gigli, Gian Luigi [3 ]
Pucillo, Carlo Ennio [4 ]
Valente, Mariarosaria [1 ,3 ]
机构
[1] Santa Maria Misericordia Univ Hosp, Clin Neurol Unit, I-33100 Udine, Italy
[2] Santa Maria Misericordia Univ Hosp, Neurol Unit, I-33100 Udine, Italy
[3] Univ Udine, Dept Med DMED, Neurol Unit, I-33100 Udine, Italy
[4] Univ Udine, Dept Med DMED, Immunol, I-33100 Udine, Italy
关键词
multiple sclerosis; Ocrelizumab; Rituximab; anti-CD20; NK cells;
D O I
10.3390/ph17020150
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Recently, research on the pathogenesis of multiple sclerosis (MS) has focused on the role of B lymphocytes and the possibility of using specific drugs, such as Ocrelizumab and Rituximab, directed toward these cells to reduce inflammation and to slow disease progression. Objective: We aimed to evaluate the effect of Ocrelizumab/Rituximab on laboratory immune parameters and identify the predictors of treatment responses. Methods: A retrospective single-center study was conducted among patients who received infusion therapy with an anti-CD20 drug to treat MS. Results: A total of 64 patients met the inclusion criteria, with 277 total cycles of therapy studied. Compared with the baseline values, anti-CD20 infusions resulted in absolute-value and percentage decreases in B lymphocyte levels and increased the absolute and percentage levels of NK cells 3 and 5 months after therapy (p < 0.001). After multivariate logistic regression analysis, a reduced percentage level of NK cells 3 months after infusion could predict disease activity 6 months after Ocrelizumab/Rituximab administration (p = 0.041). Conclusions: Lower percentage levels of NK cells 3 months after anti-CD20 infusion correlate with the presence of disease activity 6 months after therapy, confirming a possible protective role of NK cells in MS.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
    Benjamin Turner
    Bruce A. C. Cree
    Ludwig Kappos
    Xavier Montalban
    Caroline Papeix
    Jerry S. Wolinsky
    Regine Buffels
    Damian Fiore
    Hideki Garren
    Jian Han
    Stephen L. Hauser
    Journal of Neurology, 2019, 266 : 1182 - 1193
  • [22] Association of vitamin D serum levels and vitamin D supplementation with B cell kinetics and disease activity in Multiple Sclerosis patients treated with ocrelizumab: an Italian multi-center study
    Miele, Giuseppina
    Abbadessa, Gianmarco
    Cavalla, Paola
    Valentino, Paola
    Marfia, Girolama Alessandra
    Landi, Doriana
    Bosa, Chiara
    Vercellino, Marco
    De Martino, Antonio
    Ponzano, Marta
    Lavorgna, Luigi
    Bonavita, Simona
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
  • [23] Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity
    Juto, Alexander
    Fink, Katharina
    Al Nimer, Faiez
    Piehl, Fredrik
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 37
  • [24] Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab
    Auer, Michael
    Bsteh, Gabriel
    Hegen, Harald
    Wurth, Sebastian
    Zinganell, Anne
    Berger, Thomas
    Deisenhammer, Florian
    Di Pauli, Franziska
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 43
  • [25] Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
    Mansour A. Alharbi
    Fahad Aldosari
    Ahmed Hasan Althobaiti
    Faris M. Abdullah
    Salman Aljarallah
    Nuha M. Alkhawajah
    Miteb Alanazi
    Yazed AlRuthia
    BMC Health Services Research, 23
  • [26] Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis
    Graille-Avy, Lisa
    Boutiere, Clemence
    Rigollet, Camille
    Perriguey, Marine
    Rico, Audrey
    Demortiere, Sarah
    Durozard, Pierre
    Hilezian, Frederic
    Vely, Frederic
    Bertault-Peres, Pierre
    Pelletier, Jean
    Maarouf, Adil
    Audoin, Bertrand
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2024, 11 (03): : e200231
  • [27] Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
    Alharbi, Mansour A.
    Aldosari, Fahad
    Althobaiti, Ahmed Hasan
    Abdullah, Faris M.
    Aljarallah, Salman
    Alkhawajah, Nuha M.
    Alanazi, Miteb
    AlRuthia, Yazed
    BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [28] Rescue Therapy Using Rituximab for Multiple Sclerosis
    Berenguer-Ruiz, Leticia
    Sempere, Angel P.
    Gimenez-Martinez, Juana
    Gabaldon-Torres, Laura
    Tahoces, Luisa
    Sanchez-Perez, Rosa
    Diaz-Marin, Carmen
    CLINICAL NEUROPHARMACOLOGY, 2016, 39 (04) : 178 - 181
  • [29] Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction
    Toncev, G
    Milicic, B
    Toncev, S
    Samardzic, G
    EUROPEAN JOURNAL OF NEUROLOGY, 2002, 9 (03) : 221 - 226
  • [30] New directions in ocrelizumab therapy in multiple sclerosis: higher doses and subcutaneous therapy
    Selmaj, Krzysztof
    Selmaj, Igor
    AKTUALNOSCI NEUROLOGICZNE, 2023, 23 (03): : 118 - 124